drugset
drugset / Trial / NCT01419457

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

NCT01419457 ↗

Phase 1 Completed 36 enrolled MDVI, LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study is designed to determine the pharmacokinetics of favipiravir in volunteers with hepatic impairment and in healthy control volunteers.

Timeline

Start
2011-08
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Favipiravir Small molecule 400 mg —
Subject Favipiravir Small molecule 800 mg —

Indications

No indication recorded.